Alvotech (ALVO) has released an update.
STADA and Alvotech have announced the launch of Uzpruvo, Europe’s first approved biosimilar to Stelara, targeting a €2.4 billion market for treatments in gastroenterology, dermatology, and rheumatology. The launch capitalizes on the expiry of exclusivity rights for the original molecule, aiming to increase patient access and reduce healthcare costs. Uzpruvo, which is manufactured in Europe, offers a pre-filled syringe with a thinner needle and is latex-free, enhancing patient comfort.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
